anti-Titin-Antibody ELISA Kit

Sample

Serum, Plasma

Species Reactivity

Human

Intended Use

Enzyme Immunoassay for the Determination of anti-Titin-Antibodies in Serum and Plasma

Storage

On arrival, store the kit at 2-8 °C. Once opened the kit is stable until its expiry date. For stability of prepared reagents refer to Preparation of Reagents.
Allow all reagents to reach room temperature before use.

Precision

Intra-Assay-cv (%): 2.3 – 2.8 %
Inter-Assay-cv (%): 8.1 – 15.8 %

General Description

In about 80 % of patients with Myasthenia gravis alterations of the thymus can be detected. Approximately 10 % of these patients develop thymus neoplasia as thymic epithelial tumor (TET) or thymic carcinoma. An early diagnosis of the thymoma and subsequent thymectomy is decisive for the prognosis of these patients.
Most of the affected patients develop acetylcholine receptor antibodies which can be detected with the ACHRAB-Assay for the diagnosis of myasthenia gravis, as well as autoantibodies against striated muscles, among others antibodies to titin.
Titin is a protein of the striated muscles with an extremely high molecular weight. The immunogenic region of titin is located on a 30 kD protein fragment. Antibodies against this fragment presumably crossreact with the epitopes of the acetylcholine receptors (paraneoplastic myasthenia gravis). The recombinant MGT30 peptide is used in the ELISA for the specific determination of anti-titin antibodies.
The new ELISA assay is clearly superior to the immunofluorescence test on sections of striated human or monkey muscles.